OneSource Specialty Pharma Ltd Q1 FY27 Earnings Analysis

- OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. - The company reiterated its FY28 guidance of US$400 million revenue and 40% EBITDA margin. - Expansion of injectable and soft gel capacities, including three DDC lines by end of FY27, will drive sequential quarter-on-quarter revenue and EBITDA improvement. - Demand-supply gap expected to persist for at least the next 2 years, with high customer demand and capacity reservations from clients. - Biologics business shows strong funnel with agreements expected in FY27 and meaningful contributions in FY28, indicating a long runway for growth. - Growing markets like Brazil, Saudi Arabia, and Turkey, along with emerging markets, offer significant untapped revenue opportunities. - Soft gel capacity expected to be fully utilized by end of the current year, with further expansions planned subsequently.

- OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards. - FY28 revenue guidance is reaffirmed at US$400 million with an EBITDA margin of around 40%. - Sequential quarterly revenue and EBITDA improvements are expected due to new capacity coming online, including two additional DDC (drug device combination) lines by end of FY27. - Capacity expansions in soft gels and injectables will drive growth and utilization, with soft gel capacity fully utilized by end of this year or early next year. - EBITDA in Q4 FY26 showed strong operating leverage with margins expanding 1,550 basis points QoQ. - FY26 adjusted PAT was INR739 million with a full year EPS of INR6.5; FY27 and beyond expected to show scaling profits and operating leverage. - The long-term target includes a 50%+ ROCE medium term, indicating strong future profitability.

- The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth. - A fourth injectable line is being introduced in Unit 2, featuring advanced capabilities like handling high viscosity pre-filled syringes. - Two additional injectable lines are planned for installation within the year, with three lines expected to be operational by end of FY27. - Capacity expansion also includes upgrading batch sizes from 200 liters to up to 750–1,000 liters, increasing output by 2.5x. - The capex for these expansions is fully funded through incremental domestic and international borrowings. - Earlier plans for related party transactions involving Steriscience and Brooks have been deferred, with a potential revisit in around two years. - The capital investments aim to scale towards the company's $400 million revenue target by FY28 and beyond.

- All capacity expansions are fully funded through incremental borrowings from domestic and international banking relationships. - The company has lowered its overall cost of borrowing to below 9%, down by 210 basis points compared to the prior year. - No mention of current or planned equity fundraising in the disclosed call; focus is on debt-funded capacity expansion. - Management indicated potential inorganic elements for growth beyond the $400 million target but did not specify fundraising modes. - No announced new equity issuance; emphasis remains on organic growth and existing funding channels for expansion.

- The company is fully committed to its current capacity, with strong visibility of robust demand across markets where approvals exist or are expected. - Customers have secured capacity reservations through upfront fees and take-or-pay contracts, indicating a firm orderbook on capacity. - Demand-supply gap expected to persist for at least the next two years, reflecting strong pending orders and order pipeline. - New manufacturing lines (two additional lines scheduled this year and another next year) are being added to meet this demand. - Capacity expansions underway in commercial manufacturing, particularly injectable lines, expected to start contributing beyond FY28. - On Semaglutide and GLP products, demand from multiple global generic and regional partners is strong but specific break-up of orders is confidential. - Overall, orderbook and pending orders are stable and growing with increasing capacity utilization anticipated by end of current fiscal year.